熱門資訊> 正文
吉利德周刊Yeztugo HIV药丸sNDA被FDA接受
2026-06-16 05:14
- The US FDA has accepted for review an application from Gilead Sciences (GILD) for a once-weekly pill version of Yeztugo (lenacapavir) for pre-exposure prophylaxis (PrEP) of HIV.
- The sNDA has an FDA action date of Feb. 2, 2027.
- The application is supported by data from the PURPOSE 1 and PURPOSE 2 trials.
- Yeztugo is currently approved as an injection. After initiation dosing, subsequent doses are given every six months.
More on Gilead Sciences
- Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
- Gilead: 'Hold' On Biktarvy Sales Growth And MM Drug Development Program
- Gilead Sciences, Inc. (GILD) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
- Merck, Gilead share positive phase 3 results from combination HIV pill
- Gilead, Lakefront complete Ouro Medicines acquisition
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
